Bio-Rad Laboratories, Inc. Class A Common Stock vs General Dynamics Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while General Dynamics Corporation trades at $370.25 (market cap $99.92B). The key difference: General Dynamics Corporation is far larger — about 12.4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and General Dynamics Corporation pays a 1.72% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | GD | |
|---|---|---|
Market Cap | $8.04B | $99.92B |
Sector | Health | Industrials |
52-Week High | $339.75 | $376.88 |
52-Week Low | $241.71 | $297.05 |
Enterprise Value | $7.85B | $106.10B |
Dividend Yield | — | 1.72% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
General Dynamics (GD) trades at $372.78, down 0.61% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.10 versus $3.67 expected, and maintains solid fundamentals including 8.07% net income margin and 17.97% ROE. Revenue growth continues, reaching $52.55 billion in 2025, with a robust backlog of $130.8 billion highlighting strong demand in naval and defense sectors.
Outlook remains positive driven by defense spending tailwinds and submarine contract momentum, though valuation multiples like P/E of 23.46 suggest limited upside near-term. Risks include execution on large contracts and geopolitical volatility. Analyst consensus is bullish with a $395.83 price target, indicating ~6% potential appreciation from current levels.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →